...
首页> 外文期刊>Annals of allergy, asthma, and immunology >The effects of particle size on measurement of airway hyperresponsiveness to methacholine
【24h】

The effects of particle size on measurement of airway hyperresponsiveness to methacholine

机译:粒径对气道对乙酰甲胆碱高反应性测量的影响

获取原文
获取原文并翻译 | 示例

摘要

Background: The effect of particle size on methacholine provocation concentration causing a decrease in forced expiratory volume of 1 second (FEV1) of 20% (PC20) is debatable. Objective: To evaluate the functional effects of 3 different particle size nebulizers on methacholine PC20. Methods: Participants were randomly assigned to have 3 methacholine challenges on 3 separate days. Nebulizer mass median aerodynamic diameter (MMAD) was provided by manufacturers. The Wright nebulizer (MMAD, 1.0 μm), Aeroneb (MMAD, 3 μm), and Aeroneb (MMAD, 5 μm) were calibrated, and the nebulizer outputs were calculated to administer 0.26 mL of methacholine over 120, 112, and 83 seconds, respectively. After each inhalation, spirometry was performed and the test was terminated when the PC20 was achieved. Results: Eight nonsmoking patients with mild asthma (4 male and 4 female) completed the study. The mean (SD) age was 25 (13.9) years, and the mean (SD) baseline FEV1 was 88% (11.3%). Patients using the Aeroneb (MMAD, 5 μm) nebulizer had the lowest PC20 (bronchoconstricted at lowest methacholine concentration), with a PC20 geometric mean of 0.62 mg/mL compared with patients using the Aeroneb (MMAD, 3.0 μm), who had a PC 20 of 1.76 mg/mL, and patients using the Wright nebulizer (MMAD, 1.0 μm), who had a PC20 of 6.32 mg/mL. There was a significant difference in PC20 across all particle sizes (P .001). The pairwise differences revealed a P .001 between 3 μm and 1 μm and between 5 μm and 1 μm and a P =.008 between 5 μm and 3 μm. Conclusion: Our results reveal a variability in methacholine PC20 using 3 different nebulizers, despite adjusting the nebulizers' outputs. Our results are consistent with the previous reports, which recommended using larger particle size nebulizers in the assessment of airway hyperresponsiveness in asthma. Trial Registration: clinicaltrials.gov Identifier: NCT00529477.
机译:背景:粒径对乙酰甲胆碱激发浓度的影响,导致1秒的强制呼气量(FEV1)降低20%(PC20),这一点值得商bat。目的:评估3种不同粒径的雾化器对乙酰甲胆碱PC20的功能效果。方法:参与者被随机分配为在3天中分别进行3次乙酰甲胆碱挑战。雾化器质量中位空气动力学直径(MMAD)由制造商提供。对Wright雾化器(MMAD,1.0μm),Aeroneb(MMAD,3μm)和Aeroneb(MMAD,5μm)进行校准,并计算出雾化器输出以在120、112和83秒内施用0.26 mL乙酰甲胆碱,分别。每次吸入后,进行肺活量测定并在达到PC20时终止测试。结果:8例轻度哮喘的非吸烟患者(4例男性和4例女性)完成了研究。平均(SD)年龄为25(13.9)岁,平均(SD)基线FEV1为88%(11.3%)。使用Aeroneb(MMAD,5μm)雾化器的患者与使用PC的Aeroneb(MMAD,3.0μm)的患者相比,PC20最低(支气管收缩在最低乙酰甲胆碱浓度下),PC20几何平均值为0.62 mg / mL 20个(1.76 mg / mL),以及使用Wright雾化器(MMAD,1.0μm)的患者的PC20为6.32 mg / mL。在所有粒径下,PC20均存在显着差异(P <.001)。成对差异显示3μm和1μm之间以及5μm和1μm之间的P <.001和5μm和3μm之间的P = .008。结论:我们的结果显示,尽管调节了雾化器的输出,但使用3种不同的雾化器的乙酰甲胆碱PC20仍存在差异。我们的结果与以前的报告一致,该报告建议使用较大粒径的雾化器评估哮喘的气道高反应性。试用注册:clinicaltrials.gov标识符:NCT00529477。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号